ELDN Eledon Pharmaceuticals, Inc.
USHealthcareAs of 2026-08-24
Why ELDN matters now
Eledon Pharmaceuticals, Inc. (ELDN) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.41 with -1.16% on the session and $263.2M in market capitalization; recent performance reads 1-month +9.50% and YTD +159.60%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-39.0M, and EPS of $-0.35. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -29.3%.
The latest indexable market news headline is "Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $5.00; recent insider activity includes Robinson James A. Jr. filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.39
P/S
0.00
EV/EBITDA
-2.94
DCF Value
$0.24
FCF Yield
-29.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-96.8%
ROA
-53.3%
ROIC
-64.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-39.0M | $-0.35 |
| Q4 2025 | $0.00 | $-10.4M | $-0.14 |
| FY 2025 | $0.00 | $-45.6M | $-0.56 |
| Q3 2025 | $0.00 | $-17.5M | $-0.23 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$5.00
Target (Median)
$5.00
Target Range
$5.00 - $5.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.97
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.